Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. explains what axalimogene filolisbac is and the use of it in cervical cancer, specifically in the AIM2CERV trial. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Advertisement